---
title: Radiomics for residual tumour detection and prognosis in newly diagnosed glioblastoma
  based on postoperative [<sup>11</sup>C] methionine PET and T1c-w MRI
date: '2024-02-25'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38403632/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240226170504&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Personalized treatment strategies based on non-invasive biomarkers have
  potential to improve patient management in patients with newly diagnosed glioblastoma
  (GBM). The residual tumour burden after surgery in GBM patients is a prognostic
  imaging biomarker. However, in clinical patient management, its assessment is a
  manual and time-consuming process that is at risk of inter-rater variability. Furthermore,
  the prediction of patient outcome prior to radiotherapy may identify patient subgroups
  ...
disable_comments: true
---
Personalized treatment strategies based on non-invasive biomarkers have potential to improve patient management in patients with newly diagnosed glioblastoma (GBM). The residual tumour burden after surgery in GBM patients is a prognostic imaging biomarker. However, in clinical patient management, its assessment is a manual and time-consuming process that is at risk of inter-rater variability. Furthermore, the prediction of patient outcome prior to radiotherapy may identify patient subgroups ...